FY2022 EPS Estimates for Aclaris Therapeutics Inc Lowered by Jefferies Financial Group (ACRS)

Aclaris Therapeutics Inc (NASDAQ:ACRS) – Investment analysts at Jefferies Financial Group decreased their FY2022 EPS estimates for Aclaris Therapeutics in a research note issued to investors on Wednesday, November 7th. Jefferies Financial Group analyst D. Steinberg now expects that the biotechnology company will post earnings per share of $2.04 for the year, down from their previous estimate of $2.08.

Several other brokerages have also recently issued reports on ACRS. Cantor Fitzgerald reissued a “buy” rating on shares of Aclaris Therapeutics in a report on Tuesday, July 17th. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. BidaskClub cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 31st. Finally, JMP Securities reduced their target price on shares of Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating for the company in a report on Tuesday, October 16th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $40.40.

Shares of Aclaris Therapeutics stock opened at $10.62 on Thursday. Aclaris Therapeutics has a 1 year low of $10.52 and a 1 year high of $26.25. The firm has a market cap of $372.39 million, a P/E ratio of -4.25 and a beta of 1.50.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.25) by $0.19. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%. The firm had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $1.58 million.

In other Aclaris Therapeutics news, Director Stephen A. Tullman bought 6,600 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, August 23rd. The stock was purchased at an average price of $15.00 per share, with a total value of $99,000.00. Following the completion of the acquisition, the director now directly owns 170,357 shares in the company, valued at approximately $2,555,355. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anand Mehra purchased 372,093 shares of the company’s stock in a transaction that occurred on Monday, October 22nd. The shares were purchased at an average price of $10.75 per share, for a total transaction of $3,999,999.75. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 392,043 shares of company stock valued at $4,298,212. 17.00% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC grew its position in Aclaris Therapeutics by 32.7% during the second quarter. MetLife Investment Advisors LLC now owns 13,157 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 3,244 shares during the period. Russell Investments Group Ltd. grew its position in Aclaris Therapeutics by 7.4% during the first quarter. Russell Investments Group Ltd. now owns 49,450 shares of the biotechnology company’s stock valued at $867,000 after buying an additional 3,421 shares during the period. Alps Advisors Inc. grew its position in Aclaris Therapeutics by 8.4% during the second quarter. Alps Advisors Inc. now owns 44,847 shares of the biotechnology company’s stock valued at $896,000 after buying an additional 3,478 shares during the period. Metropolitan Life Insurance Co. NY grew its position in Aclaris Therapeutics by 48.1% during the second quarter. Metropolitan Life Insurance Co. NY now owns 11,056 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 3,589 shares during the period. Finally, Cadence Capital Management LLC grew its position in Aclaris Therapeutics by 12.1% during the second quarter. Cadence Capital Management LLC now owns 33,286 shares of the biotechnology company’s stock valued at $665,000 after buying an additional 3,593 shares during the period. Institutional investors own 99.83% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

See Also: Trading Penny Stocks

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply